Publications 2009
J. Schemies, U. Uciechowska, W. Sippl and M. Jung. NAD+ dependent histone deacetylases (sirtuins) as novel therapeutic target. Med Res Rev, 2009, DOI 10.1002/med.20178
P. Dubreuil, S. Letard, M. Ciufolini, L. Gros, P. S. Leventhal, M. Humbert, N. Castéran, B. Hajem, W. Sippl, C. Auclair, A. Moussy, O. Hermine. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting c-Kit. PlosOne, 2009, 4, e7258.
E.F.F da Cunha, W. Sippl, T. de Castro Ramalho, O.A.C. Antunes, R. Bicca de Alencastro, M.G. Albuquerque. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes. Eur. J. Med. Chem, 2009, 44, 4344- 4352
A. Spannhoff, A.-T. Hauser, R. Heinke, W. Sippl, M. Jung. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. Chem.Med.Chem. 2009, 4, 1568-1582.
W. Sippl. 3D-QSAR, applications, recent advances, and limitations.
In: Recent Advances in QSAR studies - Methods and applications. Eds: Puzyn, T., Cronin, M., Lesczynski, J., Springer, London, UK, 2009.
C. Göllner, C. Philipp, B. Dobner, W. Sippl and M. Schmidt. First total synthesis of 1,2-dipalmitoyl-3-(N-palmitoyl-6-deoxy-6-amino-a-D-glucosyl)glycerol - a glycoglycerolipid of a marine alga with a high inhibitor activity against human Myt1-kinase. Carbohydr. Res. 2009, 344, 1628-31.
F. Colland, E. Formstecher, X. Jacq, C. Reverdy, C. Planquette, S. Conrath, V. Trouplin, J. Bianchi, V. Aushev, J. Camonis, W. Sippl, C. Borg-Capra, V. Collura, G. Boissy, J.C. Rain, P. Guedat, R. Delansorne, L. Daviet. Small molecule inhibitor of USP7/HAUSP Ubiquitin Protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 2009, 8, 2286-95.
M. Jung and W. Sippl. Epigenetic Targets in Drug Discovery
In Methods and Principles in MedicinalChemistry - Series Eds.: Hugo Kubinyi, Gerd Folkers, and Raimund Mannhold. VCH Publisher, Inc., New York, 2009.
Julia M. Wagner, Wolfgang Sippl, Manfred Jung. Lesezeichen im Buch des Lebens. Pharmazeutische Zeitung, 2009, 26, 18 -25.
J. Schemies, W. Sippl., M. Jung. Histone deacetylase inhibitors that target tubulin. Cancer Letters 2009, 280, 222-232.
K. Wichapong, M. Lindner, S. Pianwanit, S. Kokpol, W. Sippl. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur. J. Med. Chem. 2009, 44 (4), 1383-1395
S. Schäfer, L. Saunders, S. Schlimme, V. Valkov, J. Wagner, F. Kratz, W. Sippl, E. Verdin and M. Jung. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. Chem. Med. Chem. 2009, 4(2), 283-90
A. Spannhoff, W. Sippl, M. Jung. Cancer treatments of the future - inhibitors of histone methyltransferases. International J. Biochem. & Cell Biology, 2009, 41, 4-11
R. Heinke, A. Spannhoff, R. Meier, P. Trojer, I. Bauer, M. Jung, W. Sippl. Virtual Screening and Biological Characterization of Novel Histone Arginine Methyltransferase PRMT1 Inhibitors. Chem. Med. Chem., 2009, 4, 69-77